 Cocrystal Pharma Inc NASDAQ: COCP has submitted a pre-Investigational New Drug IND briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19. FDAs response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205. 